123 related articles for article (PubMed ID: 20481631)
1. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
2. Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: enantioselective synthesis and biological evaluation.
Bühler S; Goettert M; Schollmeyer D; Albrecht W; Laufer SA
J Med Chem; 2011 May; 54(9):3283-97. PubMed ID: 21449619
[TBL] [Abstract][Full Text] [Related]
3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
4. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.
Mader M; de Dios A; Shih C; Bonjouklian R; Li T; White W; López de Uralde B; Sánchez-Martinez C; del Prado M; Jaramillo C; de Diego E; Martín Cabrejas LM; Dominguez C; Montero C; Shepherd T; Dally R; Toth JE; Chatterjee A; Pleite S; Blanco-Urgoiti J; Perez L; Barberis M; Lorite MJ; Jambrina E; Nevill CR; Lee PA; Schultz RC; Wolos JA; Li LC; Campbell RM; Anderson BD
Bioorg Med Chem Lett; 2008 Jan; 18(1):179-83. PubMed ID: 18039577
[TBL] [Abstract][Full Text] [Related]
5. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
Koch P; Jahns H; Schattel V; Goettert M; Laufer S
J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles.
Pierre Koch ; Christiane Bäuerlein ; Hartmut Jank ; Stefan Laufer
J Med Chem; 2008 Sep; 51(18):5630-40. PubMed ID: 18763757
[TBL] [Abstract][Full Text] [Related]
7. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Neumann U; Rucklin G
Bioorg Med Chem Lett; 2006 Jan; 16(2):262-6. PubMed ID: 16249085
[TBL] [Abstract][Full Text] [Related]
8. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors.
Abu Thaher B; Koch P; Schattel V; Laufer S
J Med Chem; 2009 Apr; 52(8):2613-7. PubMed ID: 19301816
[TBL] [Abstract][Full Text] [Related]
9. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
11. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
12. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
[TBL] [Abstract][Full Text] [Related]
15. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity.
Laufer S; Koch P
Org Biomol Chem; 2008 Feb; 6(3):437-9. PubMed ID: 18219408
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
17. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
20. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
